(thirdQuint)Observational Study of the Use of KRYSTEXXA in Refractory Chronic Gout.

 This is a Phase 4, multicenter, open-label, single-arm observational study of KRYSTEXXA 8 mg i.

v.

 every 2 weeks in adult hyperuricemic patients with gout refractory to conventional therapy.

 Approximately 1500 patients will be enrolled in order to observe treatment of up to 500 patients at approximately 300 centers in the United States (US).

 Study duration is approximately 63 weeks, including 51 weeks of treatment and 12 weeks of follow-up.

 The proposed patient number and 1 year duration of the study will significantly extend the patient exposure to KRYSTEXXA compared with the pre-marketing controlled clinical trials.

 The design of this study follows the FDA-approved Full Prescribing Information for the use of KRYSTEXXA and allows for capturing additional data related to the safety and efficacy of KRYSTEXXA within the standard healthcare setting.

.

 Observational Study of the Use of KRYSTEXXA in Refractory Chronic Gout@highlight

The primary purpose of this study is to observe patients being treated with KRYSTEXXA in a standard healthcare setting in order to evaluate the frequency and severity of infusion reactions, anaphylaxis and immune complex related events.

 Additionally, serious adverse events associated with KRYSTEXXA therapy will be identified.

